Mesa Laboratories, Inc. (MLAB) Given $175.00 Average Price Target by Brokerages

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus target price of $175.00 for the company and are expecting that the company will post $0.61 EPS for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 158 out of 265 based on the ratings given to its competitors.

Several analysts have commented on the company. Zacks Investment Research raised Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 9th. TheStreet raised Mesa Laboratories from a “c+” rating to a “b” rating in a report on Monday, November 6th.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Sit Investment Associates Inc. grew its holdings in Mesa Laboratories by 121.4% in the fourth quarter. Sit Investment Associates Inc. now owns 4,650 shares of the medical instruments supplier’s stock valued at $578,000 after purchasing an additional 2,550 shares during the period. Thomson Horstmann & Bryant Inc. grew its holdings in Mesa Laboratories by 14.5% in the fourth quarter. Thomson Horstmann & Bryant Inc. now owns 88,379 shares of the medical instruments supplier’s stock valued at $10,985,000 after purchasing an additional 11,164 shares during the period. Susquehanna International Group LLP acquired a new stake in Mesa Laboratories in the third quarter valued at approximately $1,030,000. DF Dent & Co. Inc. grew its holdings in Mesa Laboratories by 24.0% in the third quarter. DF Dent & Co. Inc. now owns 10,536 shares of the medical instruments supplier’s stock valued at $1,573,000 after purchasing an additional 2,042 shares during the period. Finally, Allianz Asset Management GmbH grew its holdings in Mesa Laboratories by 4.1% in the third quarter. Allianz Asset Management GmbH now owns 23,250 shares of the medical instruments supplier’s stock valued at $3,472,000 after purchasing an additional 916 shares during the period. 69.79% of the stock is currently owned by institutional investors.

Shares of Mesa Laboratories (MLAB) opened at $133.66 on Tuesday. The company has a market capitalization of $505.20, a PE ratio of 48.25 and a beta of 0.42. Mesa Laboratories has a 1-year low of $113.57 and a 1-year high of $169.80. The company has a current ratio of 2.86, a quick ratio of 1.97 and a debt-to-equity ratio of 0.48.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a net margin of 11.48% and a return on equity of 14.77%. The business had revenue of $22.95 million during the quarter, compared to analyst estimates of $25.50 million. analysts predict that Mesa Laboratories will post 2.47 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Wednesday, February 28th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.48%. The ex-dividend date of this dividend is Tuesday, February 27th. Mesa Laboratories’s payout ratio is currently 23.10%.

ILLEGAL ACTIVITY NOTICE: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.com-unik.info/2018/01/16/mesa-laboratories-inc-mlab-given-175-00-average-price-target-by-brokerages.html.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit